Peter Radovich serves as the President and Chief Operating Officer at Mirum Pharmaceuticals Inc., where he plays a pivotal role in steering the company's strategic direction and operational execution. With a robust background in the biopharmaceutical industry, Radovich brings over two decades of experience to his leadership position. Prior to joining Mirum, he held significant roles at Ultragenyx Pharmaceutical Inc., where he was instrumental in advancing the company's rare disease portfolio and expanding its global reach. His expertise in navigating the complexities of drug development and commercialization has been crucial in positioning Mirum as a leader in the treatment of rare liver diseases. At Mirum Pharmaceuticals, Radovich has been at the forefront of driving the company's mission to transform the lives of patients with rare liver diseases. Under his leadership, Mirum has successfully advanced its pipeline of innovative therapies, including the development and commercialization of Livmarli, a breakthrough treatment for Alagille syndrome. Radovich's strategic vision and operational acumen have been essential in forging key partnerships and securing regulatory approvals that have expanded the company's therapeutic offerings. His commitment to excellence and patient-centric approach continues to guide Mirum's growth and impact in the biopharmaceutical landscape.